Managing Consent and Risk Around Medication in Older People’s Services: Refusal, Review and Safeguards
Medication support is one of the most scrutinised areas of older people’s services. Errors, refusals or unclear consent can escalate quickly into safeguarding enquiries, complaints or inspection findings. Providers must balance clinical safety with autonomy, avoiding both coercive practice and unmanaged risk. This article sits within Safeguarding, Capacity, Consent & Human Rights and aligns with structured care and risk planning approaches in Person-Centred Planning in Social Care | 7-Part Guide for Providers, ensuring medication decisions are lawful, reviewable and embedded in day-to-day practice.
Why medication consent is an operational risk area
Medication issues rarely arise from a single missed dose. They develop through patterns: repeated refusals, rushed administration, assumptions about “best interests”, or unclear escalation when risks increase. In older people’s services, delirium, pain, swallowing difficulty, polypharmacy and sensory impairment all affect consent and engagement.
A defensible service can explain not only what medication is given, but how consent is sought, how refusals are managed, and how decisions are reviewed when circumstances change.
Consent, capacity and medicines: decision-specific thinking
Consent to medication is decision-specific and time-specific. A person may understand and agree to pain relief but not preventative medication, or consent in the morning but refuse later when fatigued or distressed.
Operationally, staff should be able to evidence how medication was explained, how understanding was checked, what alternatives were offered, and when capacity was reconsidered rather than assumed.
Operational example 1: Repeated refusal of essential medication
Context: A person frequently refuses cardiac medication in the late afternoon, stating they “don’t need it anymore”. Family accuse staff of neglect and demand enforcement.
Support approach: The service treats refusal as a pattern requiring analysis, not non-compliance. Consent and capacity are considered for each decision, alongside potential triggers.
Day-to-day delivery detail: Staff record timing and context of refusals, noting fatigue, pain and environmental factors. Medication is re-offered earlier with a familiar staff member, using simple explanations and visual prompts. The prescriber reviews timing and side effects. The care plan includes a refusal protocol with clear escalation thresholds.
How effectiveness or change is evidenced: MAR records show improved acceptance and reduced distress. Governance audits confirm refusals are recorded with rationale and review, not just ticked as “refused”.
When refusal becomes a safeguarding concern
Refusal alone is not safeguarding. It becomes safeguarding when serious harm risk emerges, when coercion or misunderstanding is suspected, or when staff responses become inconsistent or unsafe.
Operational example 2: Refusal linked to delirium and infection risk
Context: A person with fluctuating delirium refuses antibiotics and fluids, becomes increasingly unwell and cannot explain their reasoning clearly.
Support approach: The service treats this as combined clinical, MCA and safeguarding risk requiring prompt escalation.
Day-to-day delivery detail: Staff document delirium indicators, reassess capacity for the specific decision, and involve health professionals. Where capacity is lacking, a best interests decision is made with clinical input, time limits and daily review.
How effectiveness or change is evidenced: Records show clinical improvement, reduced delirium and clear best interests reasoning with review dates.
Covert medication: safeguarding, not convenience
Covert administration is one of the highest-risk practices in older people’s services. It must never be used to manage workload or routine refusal.
Operational example 3: Proposal for covert medication
Context: Staff suggest covert medication because refusals disrupt routines.
Support approach: The Registered Manager initiates a formal best interests process with clinical and pharmacy oversight.
Day-to-day delivery detail: Alternatives are trialled first. Only if capacity is lacking and risks remain is covert medication considered, with defined scope, dignity safeguards and a short review cycle.
How effectiveness or change is evidenced: Governance records show covert use is rare, time-limited and discontinued where possible, with audit oversight.
Commissioner and regulator expectations
Commissioner expectation: Providers can evidence safe medication systems that respect consent, manage refusal proportionately and escalate risks appropriately.
Regulator / inspector expectation (e.g. CQC): Inspectors expect refusals to be respected and managed lawfully, with covert medication exceptional, justified and reviewed.
Governance and assurance mechanisms
Strong governance includes MAR audits focused on refusal quality, medication reviews, staff training on consent and capacity, and senior oversight of high-risk decisions. Outcomes tracked include distress reduction, adherence patterns and safeguarding escalation rates.